Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
bioXXmed AGHAM:T5O 33 PB Ratio is 192.50 as of Jul. 16, 2026, which is 9200% above its 10-year median of 2.07. GuruFocus rates HAM:T5O with a GF Score™ of 33/100 and a GF Value™ of €9.07 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,227 Biotechnology companies, bioXXmed AG ranks worse than 99.51% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-16), bioXXmed AG's share price is €0.77. bioXXmed AG's Book Value per Share for the quarter that ended in Dec. 2025 was €0.00. Hence, bioXXmed AG's PB Ratio of today is 192.50.
The historical rank and industry rank for bioXXmed AG's PB Ratio or its related term are showing as below:
HAM:T5O'
s PB Ratio Range Over the Past 10 Years
Min: 0.09 Med: 2.07 Max: 340
Current: 192.5
During the past 13 years, bioXXmed AG's highest PB Ratio was 340.00. The lowest was 0.09. And the median was 2.07.
HAM:T5O's PB Ratio is ranked worse than 99.51% of 1227
companies
in the Biotechnology industry
Industry Median: 2.93
vs HAM:T5O: 192.50
During the past 12 months, bioXXmed AG's average Book Value Per Share Growth Rate was -99.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -97.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -88.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -55.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of bioXXmed AG was 35.30% per year. The lowest was -97.20% per year. And the median was -1.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
bioXXmed AG PB Ratio Related Terms
bioXXmed AG PB Ratio Historical Data
* Premium members only.
The historical data trend for bioXXmed AG's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, bioXXmed AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
bioXXmed AG PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, bioXXmed AG's PB Ratio distribution charts can be found below:
* The bar in red indicates where bioXXmed AG's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
bioXXmed AG's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
bioXXmed AG (HAM:T5O) has a PB Ratio of 192.50 as of Jul. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on bioXXmed AG and its competitors. This is 9200% above median its historical median of 2.07. Over the past decade, bioXXmed AG's PB Ratio has ranged from 0.09 to 340.00. According to the industry distribution chart, bioXXmed AG ranks #1221 out of 1227 companies in the Biotechnology industry, placing it in the top 99.5%.
Is bioXXmed AG's PB Ratio too high?
bioXXmed AG's current PB Ratio of 192.50 is 9200% above median its 10-year median of 2.07. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 340.00. The Biotechnology industry median PB Ratio is 2.93. bioXXmed AG's value of 192.50 is 6470% above this industry median. Based on the distribution chart, bioXXmed AG ranks #1221 out of 1227 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, bioXXmed AG has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does bioXXmed AG's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, bioXXmed AG ranks #1221 out of 1227 companies for PB Ratio. This places bioXXmed AG in the lower half of its industry. The industry median PB Ratio is 2.93. bioXXmed AG's value of 192.50 is 6470% above this benchmark. Historically, bioXXmed AG's own PB Ratio has ranged from 0.09 to 340.00 over the past decade. While the company's 10-year median is 2.07 vs. the industry median of 2.93, bioXXmed AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. bioXXmed AG's current PB Ratio of 192.50 is 6470% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on bioXXmed AG and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. bioXXmed AG's current PB Ratio is 192.50, which is 9200% above median its own 10-year median of 2.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioXXmed AG stock overvalued right now?
Based on GuruFocus' analysis, bioXXmed AG (HAM:T5O) is currently considered Possible Value Trap. The stock's GF Value™ is €9.07, compared to a current price of €0.77 — trading 91.5% below its estimated fair value. The current PB Ratio is 192.50, which is 9200% above median its 10-year median of 2.07 and 6470% above the Biotechnology industry median of 2.93. bioXXmed AG's overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For bioXXmed AG (HAM:T5O), the current PB Ratio is 192.50 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is bioXXmed AG (HAM:T5O) Overvalued in 2026?
Based on GuruFocus' analysis, bioXXmed AG stock appears to be undervalued.
The current stock price of €0.77 is trading 91.5% below its estimated GF Value™ of €9.07.
GuruFocus considers bioXXmed AG to be Possible Value Trap.
Key valuation signals for HAM:T5O:
PB Ratio: 192.50 (9200% above median its 10-year median of 2.07)
GF Value™: €9.07 vs. price of €0.77 (91.5% below fair value)
Industry Position: 6470% above the Biotechnology median (#1221 of 1227)
No single metric tells the full story. See the HAM:T5O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
bioXXmed AG is an investment and holding company in the technology sector. It originated from CytoTools GmbH, a successful German technology enterprise from the pharmaceuticals and medical products field.
33GF Score
Get the complete analysis for HAM:T5O
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:T5O has been successfully added to your 
